Table 3.
Discriminant analysis of combinations of candidate miRNAs showing the highest accuracy for each number of miRNAs used (1–3) as predictive markers of recurrence in patients with BTC.
| Discriminant | Accuracy (%) | Sensitivity (%) | Specificity (%) | AUC |
|---|---|---|---|---|
| miR-1225-3p | 81.8 | 76.9 | 88.9 | 0.744 |
| miR-6875-5p | 81.8 | 76.9 | 88.9 | 0.778 |
| miR-1470, miR-6834-3p | 86.4 | 92.3 | 77.8 | 0.829 |
| miR-1225-3p, miR-1260b, miR-6875-5p | 90.9 | 84.6 | 100.0 | 0.897 |
| miR-1260b, miR-6834-3p, miR-6875-5p | 90.9 | 84.6 | 100.0 | 0.880 |
| CEA value at diagnosis | 68.2 | 76.9 | 55.6 | 0.668 |
| CA19-9 value at diagnosis | 68.2 | 76.9 | 55.6 | 0.632 |
Abbreviations: BTC, bile tract cancer; AUC, area under the curve; CEA, carcinoembryonic antigen; CA19-9, carbohydrate antigen 19-9.